Key result
High ANGPTL4 expression linked to ~40% worse overall survival and advanced features across multiple cancers.
Why the study?
Despite numerous studies suggesting the involvement of ANGPTL4 in cancer, its definitive role across various cancer types remains unclear.
Is increased ANGPTL4 expression associated with worse prognosis and tumor progression in cancer patients?
Population
Patients across various cancer types from observational studies and bioinformatics databases
Comparison
Increased ANGPTL4 expression vs lower or baseline expression
Design
Meta-analysis of observational studies and pan-cancer bioinformatics study
Authors
Loading...
May refine prognostic stratification across cancers; extends observational data but leaves therapeutic targeting unproven.
Meta-Analysis (n=3,268)
Is increased ANGPTL4 expression associated with worse prognosis and tumor progression in cancer patients?
Hazard Ratio: 1.4 (95% CI 1.29–1.5)
p-value: p=0.0001
Increased ANGPTL4 expression is associated with worse overall survival and tumor progression across various cancers, suggesting it as a potential therapeutic target.
Younis et al. (2025) conducted a meta-analysis in Cancer (n=3,268). High ANGPTL4 expression vs. Low ANGPTL4 expression was evaluated on Overall survival (HR 1.40, 95% CI 1.29-1.50, p=0.0001). High ANGPTL4 expression was significantly associated with worse overall survival (HR 1.40) and advanced clinicopathological features across multiple cancer types.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: